
Special Report: Preparing for Stage 1 of the FDA’s LDTs Final Rule
Considerations for addressing compliance with Stage 1 of the FDA’s lab-developed tests final rule
Considerations for addressing compliance with Stage 1 of the FDA’s lab-developed tests final rule
Regulatory expert explores whether any exclusions might benefit cancer laboratories trying to navigate upcoming compliance deadlines
Understanding the process and implementing proper procedures is the key to ensuring compliance when reporting such events
FDA seems determined to push ahead with final rule, regardless of CDRH director’s departure, hiring of replacement.
CEO Laurie Menser discusses the Association for Molecular Pathology’s court case against the FDA’s rule on laboratory-developed tests.